Aripiprazole in autism: safety and tolerability
Downloads
Published
2012-03-30
How to Cite
Vidal Formoso, M., & Montañés Rada, F. (2012). Aripiprazole in autism: safety and tolerability. Revista De Psiquiatría Infanto-Juvenil, 29(1), 25–33. Retrieved from https://aepnya.eu/index.php/revistaaepnya/article/view/238
Issue
Section
Review article
Keywords:
Aripiprazole, treatment, children, autistic disorderAbstract
The aim of this study is to do a review on the efficacy and security of aripiprazole in the treatment of symptoms of irritability associated with autistic disorder. Improvements in other symptoms included on the Aberrant Behavior Checklist (ABC) are revised as well. In order to do this we have reviewed three studies. The first two are 8-week, randomized, double-blind, multicenter trials to evaluate the efficacy of both aripiprazole fixed doses (5 mg/d, 10mg/d, 15mg/d) and flexible doses (2-15mg/d) versus a placebo. The third study was a post hoc analysis of the two former, and it evaluated the effect of aripiprazol on the 58 items the ABC scale. The results were significant with aripiprazole versus a placebo on the following ABC scale items and with all aripiprazole doses used: mood changes quickly, cries/screams, stamps feet, repetitive movement, boisterous, constantly runs or jumps, and tends to be excessively active. Furthermore with the 15mg/d dose significant results were obtained for a greater number of items.
Downloads
Download data is not yet available.
References
1. Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children: confirmation of high prevalence. Am J Psychiatry. 2005;162(6):1133–1141
2. Fombonne E, Zakarian R, Bennett A, Meng L, McLean-Heywood D. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics. 2006;118(1). Available at:1/e139
3. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314–321
4. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004; 114 (5). Available at: 5/e634
5. Broadstock M, Doughty C. The effectiveness of pharmacological therapies for young people and adults with autism spectrum disorder (ASD):a critical appraisal of the literature. Christchurch: New Zealand Health Technology Assessment; 2003. p. 77.
6. BarnardL, Young A H, Pearson J, Geddes J, O’Brien G. A systematic review of the use of atypical antipsychotics in autism. J Psychopharmacol 2002; 16:93-101.37.
7. McCracken J T, McGough J, Shah B, Cronin P, Hong D, Aman M G, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347:314-21.
8. Findling RL, Kauffman RE, Sallee FR, et al. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study. J ClinPsychopharmacol.2008;28(4):441–446
9. Findling RL, Robb A, Nyilas M, et al. A multiplecenter, randomized, double-blind, placebo-con trolled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008; 165(11):1432–1441
10. Biederman J, Mick E, Spencer T, et al. An openlabel trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectr. 2007;12(9): 683–689
11. Biederman J, McDonnell MA, Wozniak J, et al. Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. CNS Spectr. 2005;10(2):141–148
12. Valicenti - McDermott MR, Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. j Child Adolesc Psychopharmacol. 2006;16: 549-560.
13. Stigler KA, Posey DJ, McDougle CJ. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004; 14:455-463.
14. Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, Aman MG: A placebo controlled fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48:1110-1119, 2009.
15. Owen R, Sikich l, Marcus R.N. Corey P, George L, McQuade R.D., Findling R.L. Aripiprazol in the treatment of irritability in children and adolescents with autistic disorder. Pedriatrics 2009; 124; 1533- 1540.
16. Aman M G, Kasper W, Manos G, Mathew S, Marcus R, Owen R, Mankoski R. Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder. Journal of child and adolescent psychopharmacology. 2010. Volume 20, Number 5:415-422.
17. Aman MG, Singh NN. Aberrant Behavior Checklist: Manual. East Aurora, NY: Slosson Educational Publications; 1986
18. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview–Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord.1994;24(5):659–685
19. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970; 212:11-19.
20. G. Barnes TR. A rating scale for drug-induced akathisia. Br j Psychiatry. 1989; 154:672-676.
21. Guy W. Abnormal Involuntary Movement Scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health; 1976: 534-537. US Department of Health, Education, and Welfare publication (ADM) 76-338.
2. Fombonne E, Zakarian R, Bennett A, Meng L, McLean-Heywood D. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics. 2006;118(1). Available at:1/e139
3. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314–321
4. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004; 114 (5). Available at: 5/e634
5. Broadstock M, Doughty C. The effectiveness of pharmacological therapies for young people and adults with autism spectrum disorder (ASD):a critical appraisal of the literature. Christchurch: New Zealand Health Technology Assessment; 2003. p. 77.
6. BarnardL, Young A H, Pearson J, Geddes J, O’Brien G. A systematic review of the use of atypical antipsychotics in autism. J Psychopharmacol 2002; 16:93-101.37.
7. McCracken J T, McGough J, Shah B, Cronin P, Hong D, Aman M G, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347:314-21.
8. Findling RL, Kauffman RE, Sallee FR, et al. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study. J ClinPsychopharmacol.2008;28(4):441–446
9. Findling RL, Robb A, Nyilas M, et al. A multiplecenter, randomized, double-blind, placebo-con trolled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008; 165(11):1432–1441
10. Biederman J, Mick E, Spencer T, et al. An openlabel trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectr. 2007;12(9): 683–689
11. Biederman J, McDonnell MA, Wozniak J, et al. Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. CNS Spectr. 2005;10(2):141–148
12. Valicenti - McDermott MR, Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. j Child Adolesc Psychopharmacol. 2006;16: 549-560.
13. Stigler KA, Posey DJ, McDougle CJ. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004; 14:455-463.
14. Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, Aman MG: A placebo controlled fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48:1110-1119, 2009.
15. Owen R, Sikich l, Marcus R.N. Corey P, George L, McQuade R.D., Findling R.L. Aripiprazol in the treatment of irritability in children and adolescents with autistic disorder. Pedriatrics 2009; 124; 1533- 1540.
16. Aman M G, Kasper W, Manos G, Mathew S, Marcus R, Owen R, Mankoski R. Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder. Journal of child and adolescent psychopharmacology. 2010. Volume 20, Number 5:415-422.
17. Aman MG, Singh NN. Aberrant Behavior Checklist: Manual. East Aurora, NY: Slosson Educational Publications; 1986
18. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview–Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord.1994;24(5):659–685
19. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970; 212:11-19.
20. G. Barnes TR. A rating scale for drug-induced akathisia. Br j Psychiatry. 1989; 154:672-676.
21. Guy W. Abnormal Involuntary Movement Scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health; 1976: 534-537. US Department of Health, Education, and Welfare publication (ADM) 76-338.
© 2021 AEPNyA Todos los derechos reservados
